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OBJECTIVES: Epoetin alfa (EPO) and darbepoetin alfa (DARB)
are approved for the treatment of anemia in patients with
chronic kidney disease (CKD) not on dialysis; however, little is
known about their dosing patterns in the elderly population. The
objective of this analysis was to evaluate the frequency of admin-
istration, dosage, and associated drug cost of EPO and DARB in
patients ≥65 years of age with CKD not on dialysis. METHODS:
A retrospective analysis was conducted using medical claims
from approximately 30 health plans during the period of July,
2002 through February, 2004. To be included in the analysis,
patients were required to be ≥65 years old, have ≥2 EPO or
DARB claims, have a CKD diagnosis and not be on dialysis, 
have no prior cancer diagnosis, and be newly treated with either
agent. 2003 wholesale acquisition costs (WAC) were used to cal-
culate drug costs. RESULTS: 149 EPO and 35 DARB patients
met the inclusion criteria. More males were in the EPO group
(54.4% vs. 34.3%, p = 0.03). Age was similar between the
groups (mean years; EPO 74.4 ± 5.3; DARB 74.4 ± 5.6, p =
0.96), as was average therapy duration (days; EPO 86.7 ± 86.5;
DARB 81.2 ± 78.8, p = 0.73). Weekly and extended (≥Q2W)
dosing regimens were found in both groups (EPO—QW: 40.3%,
Q2W: 40.3%, ≥Q3W: 19.5%; DARB—QW: 14.3%, Q2W:
54.3%, ≥Q3W: 31.4%). The average time interval between drug
administrations was 13.0 ± 6.9 days for the EPO group and 15.6
± 5.4 days for the DARB group. The average weighted weekly
dose was 11,121 ± 10,773 Units for EPO and 46.0 ± 29.9mcg
for DARB, corresponding to an average weekly drug cost of
$124 for EPO and $184 for DARB. CONCLUSION: Extended
dosing (≥Q2W) of EPO and DARB was identiﬁed in a majority
of elderly anemic CKD patients not on dialysis, with lower drug
acquisition costs observed in the EPO group compared to the
DARB group.
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INTRODUCTION: This was a retrospective database study to
identify prescription treatment patterns for OAB in a managed
care population. METHODS: The two-year intake period was
January 1, 2001 to December 31, 2002. Members with ≥1 diag-
nosis code for OAB in medical claims and/or ≥1 prescription
claim for an OAB drug were included. All claims were collected
1 year pre- and ≥1 year post-index. RESULTS: A study cohort
of 19,486 OAB patients was identiﬁed, representing a 2% preva-
lence rate. The population was predominantly female (66%);
mean age was 56 years. Most (86%) were new OAB cases. Long-
acting OAB antimuscarinic medications were most frequently
prescribed. Among new OAB patients, 30% had ≥1 OAB-related
prescription claim(s) during follow-up. Only 9% of new OAB
patients were initiated on OAB therapy after index date; mean
time to initiation was 137 days (median 50 days). Most new
OAB patients (96%) discontinued all OAB medication; mean
time to discontinue was approximately two-months (median
one-month). Few patients were continuously on OAB therapy
(4%), switched, or added on a drug other than the initial OAB
drug (15%). CONCLUSIONS: There appears to be lack of phar-
macological intervention in OAB patients. Overall, patients were
slow to initiate treatment, remained on drug therapy brieﬂy, 
and most discontinued treatment. This may reﬂect intolerance 
of OAB pharmacological options and/or lack of efﬁcacy, non-
pharmacological management, a perception among patients
and/or physicians that OAB symptoms have little impact on
quality of life, or OAB patients may wait until symptoms become
severe before requesting treatment.
PUK18
EVALUATION OF THE RELIABILITY AND VALIDITY OF THE
INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE (I-QOL)
IN PATIENTS WITH DETRUSOR HYPERREFLEXIA
Barron R1, Slaton T2, Kozma C3, Reese P4
1Allergan Corp, Irvine, CA, USA; 2Independent Consulant, West
Columbia, SC, USA; 3Independent Consultant, West Columbia, SC,
USA; 4Reese and Associates, Cary, NC, USA
OBJECTIVES: The Incontinence Quality of life Questionnaire
(I-QOL) is a 22-item questionnaire used in patients with urinary
incontinence. Validity of the I-QOL has been demonstrated in
stress incontinence patients. The purpose of this study is to assess
I-QOL in patients with detrusor hyperreﬂexia. METHODS:
Data were from a multicenter, double-blind, randomized,
placebo-controlled, parallel group study of two Botox doses. The
I-QOL was scored according to the developer’s guidelines which
provide total score and three domain scores: avoidance and lim-
iting behavior (ALB), psychosocial impact (PS), social embar-
rassment (SE). Validity and reliability were assessed by item to
scale correlations, similarity of means and variance, reliability
(Cronbach’s alpha), ﬂoor and ceiling effects, and correlations
with clinical measures. Responsiveness was assessed by evalua-
tion of I-QOL scores for all groups. RESULTS: The majority of
patients (n = 56) were Caucasian (93%) and male (59%). All but
four items of the 22 I-QOL items were more highly correlated
with their hypothesized scale than with competing scales;
however most of the items failed to meet a criterion of “two stan-
dard errors greater”. Item means and variances were similar for
the PS and SE domains. The ALB items exhibited similar vari-
ances; however range in means was somewhat larger. Cronbach’s
alpha ranged from 0.79 to 0.89 for domains and 0.93 for the
total. There was no signiﬁcant ﬂoor or ceiling effect. Moderate
correlations (0.18 to 0.37) existed between I-QOL scores and
clinical measures (e.g., number of involuntary losses of urine,
and urodynamic parameters). CONCLUSIONS: The validity of
the I-QOL in this neurogenic bladder population is supported.
The ALB domain was not as consistent since there was a mix of
detrusor hyperreﬂexia patients in this study and one question
may not be as relevant for some patients. Additional study in
larger samples is warranted.
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OBJECTIVES: Overactive bladder (OAB) is characterized by
symptoms of urinary urgency, with or without incontinence,
urinary frequency, and nocturia. Because urinary urgency is a
hallmark symptom of OAB, it is necessary to accurately assess
its impact on patients. To this end, we assessed the content valid-
ity of the newly developed Urinary Sensation Scale (USS) for
